iCell Therapeutics is a dynamic biotechnology company dedicated to establishing new standards of care in oncology and cardiovascular treatments.

iCell's proprietary site selective Low Density Emulsion (LDE) technology and products are backed by more than 16 years of research. The technology is validated by extensive pre-clinical animal and clinical studies. These studies have generated an array of new product candidates for cancer and cardiovascular diseases.